Cocrystallization of Gefitinib Potentiate Single-Dose Oral Administration for Lung Tumor Eradication via Unbalancing the DNA Damage/Repair
Open Access
- 30 November 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (12) , 2713
Abstract
Gefitinib (GEF) is a clinical medication for the treatment of lung cancer targeting the epidermal growth factor receptor (EGFR). However, its efficacy is remarkably limited by low solubility and dissolution rates. In this study, two cocrystals of GEF with co-formers were successfully synthesized using the recrystallization method characterized via Powder X-ray Diffraction, Fourier Transform Infrared Spectroscopy, and 2D Nuclear Overhauser Effect Spectroscopy. The solubility and dissolution rates of cocrystals were found to be two times higher than those of free GEF. In vitro cytotoxicity studies revealed that the cocrystals enhanced the inhibition of cell proliferation and apoptosis in A549 and H1299 cells compared to free GEF. In mouse models, GEF@TSBO demonstrated targeted, safe, and effective antitumor activity with only one-dose administration. Mechanistically, the GEF cocrystals were shown to increase the cellular levels of damaged DNA, while potentially downregulating PARP, thereby impairing the DNA repair machinery and leading to an imbalance between DNA damage and restoration. These findings suggest that the cocrystallization of GEF could serve as a promising adjunct to significantly enhance the physicochemical and biopharmaceutical performance for lung cancer treatment, providing a facial strategy to improve GEF anticancer efficiency with high bioavailability that can be orally administrated with only one dose.Keywords
Funding Information
- High-level University Construction Fund of Guangdong Province (02-412-2302-2122XM, 02-410-2206298, 02-410-2302374XM, 02-445-2301221XM, 2023A1515011064, Q0301-082, 202201010378, SKLRD-OP-202409, SKLRD-OP-202302)
- Guangzhou Medical University (02-412-2302-2122XM, 02-410-2206298, 02-410-2302374XM, 02-445-2301221XM, 2023A1515011064, Q0301-082, 202201010378, SKLRD-OP-202409, SKLRD-OP-202302)
- Guangdong Basic and Applied Basic Research Foundation (02-412-2302-2122XM, 02-410-2206298, 02-410-2302374XM, 02-445-2301221XM, 2023A1515011064, Q0301-082, 202201010378, SKLRD-OP-202409, SKLRD-OP-202302)
- Postdoctoral Start-up Fund (02-412-2302-2122XM, 02-410-2206298, 02-410-2302374XM, 02-445-2301221XM, 2023A1515011064, Q0301-082, 202201010378, SKLRD-OP-202409, SKLRD-OP-202302)
- Guangzhou Science and Technology Bureau (02-412-2302-2122XM, 02-410-2206298, 02-410-2302374XM, 02-445-2301221XM, 2023A1515011064, Q0301-082, 202201010378, SKLRD-OP-202409, SKLRD-OP-202302)
- Open Project of State Key Laboratory of Respiratory Disease (02-412-2302-2122XM, 02-410-2206298, 02-410-2302374XM, 02-445-2301221XM, 2023A1515011064, Q0301-082, 202201010378, SKLRD-OP-202409, SKLRD-OP-202302)
This publication has 39 references indexed in Scilit:
- FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung CancerClinical Cancer Research, 2016
- Spectroscopic investigation on cocrystal formation between adenine and fumaric acid based on infrared and Raman techniquesSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2016
- Drug–Drug Molecular Salt Hydrate of an Anticancer Drug Gefitinib and a Loop Diuretic Drug Furosemide: An Alternative for Multidrug TreatmentJournal of Pharmaceutical Sciences, 2015
- Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutationLung Cancer, 2015
- A pharmaceutical cocrystal with potential anticancer activityRSC Advances, 2014
- Solubility Enhancement of Ezetimibe by a Cocrystal Engineering TechniqueCrystal Growth & Design, 2014
- Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystalsInternational Journal of Nanomedicine, 2012
- Drug Solubility: Importance and Enhancement TechniquesISRN Pharmaceutics, 2012
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- New applications of 2D filtered/edited NOESY for assignment and structure elucidation of RNA and RNA-protein complexesJournal of Biomolecular NMR, 2004